Article Text

Download PDFPDF
Randomised Controlled Trial
Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance
  1. Philip D Home
  1. ICM-Diabetes, The Medical School, Newcastle University, Newcastle upon Tyne, UK
  1. Correspondence to Professor Philip Home
    ICM-Diabetes, The Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; philip.home{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:


Type 2 diabetes has high long-team health and resource impact, as a result of its vascular complications and needed therapies. Prevention of diabetes then seems to be attractive. Previous studies have identified that lifestyle interventions and some therapeutic approaches can prevent or delay the onset of diabetes in those with hyperglycaemia. Such therapies include metformin and thiazolidinediones. Metformin and rosiglitazone are efficacious in combination in people with diabetes, while tablet combination at submaximum dose may give additive effects with reduced side effects. Zinman and colleagues asked whether such combination of these agents could prevent deterioration to diabetes in a population at risk.


Using conventional risk factors (obesity, high blood pressure and the like) to identify 992 people – screened …

View Full Text


  • Competing interests PDH provides educational, advisory and research services in association with the manufacturer of rosiglitazone.